Ibuprofen Plus Acetaminophen Versus Ibuprofen Alone for Acute Low Back Pain: An Emergency Department-based Randomized Study

Benjamin W Friedman, Eddie Irizarry, Andrew Chertoff, Carmen Feliciano, Clemencia Solorzano, Eleftheria Zias, E John Gallagher, Benjamin W Friedman, Eddie Irizarry, Andrew Chertoff, Carmen Feliciano, Clemencia Solorzano, Eleftheria Zias, E John Gallagher

Abstract

Objectives: Patients with low back pain (LBP) are often treated with nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are modestly effective for LBP, but many patients with LBP continue to suffer despite treatment with these medications. We compared pain and functional outcomes 1 week after emergency department (ED) discharge among patients randomized to a 1-week course of ibuprofen plus acetaminophen versus ibuprofen plus placebo.

Methods: This was a randomized, double-blind study conducted in two urban EDs. Patients presenting with acute, nontraumatic, nonradicular LBP of no more than 2 weeks' duration were eligible for enrollment immediately prior to discharge from an ED if they had a score > 5 on the Roland Morris Disability Questionnaire (RMDQ), a 24-item validated instrument, indicating more than minimal functional impairment. All patients were given a standardized 10-minute LBP educational session prior to discharge. The primary outcome was improvement on the RMDQ between ED discharge and 1 week later. One secondary outcome was pain intensity, as measured on a 4-point descriptive scale (severe, moderate, mild, none) at 1 week.

Results: Enrollment began in October 2018. A total of 120 patients met selection criteria and were randomized. Baseline demographic characteristics were comparable between the two groups. By 1 week after the ED visit, patients randomized to ibuprofen plus placebo reported a mean (±SD) improvement in the RMDQ of 11.9 (±9.7), while those randomized to ibuprofen plus acetaminophen reported a mean (±SD) improvement of 11.1 (±10.7). The 95% CI for the between-group difference of 0.8 was -3.0 to 4.7. At 1 week, moderate or severe pain was reported by 15 of 53 (28%) patients in the ibuprofen plus placebo group and 16 of 57 (28%) patients in the ibuprofen plus acetaminophen group (95% CI for between-group difference of 0% = -17% to 17%).

Conclusion: Among ED patients with acute, nontraumatic, nonradicular LBP, adding acetaminophen to ibuprofen does not improve outcomes within 1 week.

© 2019 by the Society for Academic Emergency Medicine.

References

    1. Friedman BW, Chilstrom M, Bijur PE, Gallagher EJ. Diagnostic testing and treatment of low back pain in United States emergency departments: a national perspective. Spine (Phila Pa 1976) 2001;35:E1406-11.
    1. Friedman BW, O'Mahony S, Mulvey L, et al. One-week and 3-month outcomes after an emergency department visit for undifferentiated musculoskeletal low back pain. Ann Emerg Med 2012;59:128-33.e3.
    1. Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA 2015;314:1572-80.
    1. Qaseem A, Wilt TJ, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017;166:514-30.
    1. Friedman BW, Irizarry E, Solorzano C, et al. Diazepam is no better than placebo when added to naproxen for acute low back pain. Ann Emerg Med 2017;70:169-76.
    1. Friedman BW, Cisewski D, Irizarry E, et al. A randomized, double-blind, placebo-controlled trial of naproxen with or without orphenadrine or methocarbamol for acute low back pain. Ann Emerg Med 2018;71:348-56.
    1. Friedman BW, Irizarry E, Solorzano C, et al. A randomized, placebo-controlled trial of ibuprofen plus metaxalone, tizanidine, or baclofen for acute low back pain. Ann Emerg Med 2019;74:512-20.
    1. Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C. Maher CG. Paracetamol for low back pain. Cochrane Database Syst Rev 2016;(6):CD012230.
    1. Roland M, Fairbank J. The Roland-Morris disability questionnaire and the Oswestry disability questionnaire. Spine (Phila Pa 1976) 2000;25:3115-24.
    1. Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976) 2008;33:90-4.
    1. Ostojic P, Radunovic G, Lazovic M, Tomanovic-Vujadinovic S. Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study. Acta Reumatol Port 2017;42:18-25.
    1. Ridderikhof ML, Lirk P, Goddijn H, et al. Acetaminophen or nonsteroidal anti-inflammatory drugs in acute musculoskeletal trauma: a multicenter, double-blind, randomized, clinical trial. Ann Emerg Med 2018;71:357-68.e8.
    1. Bondarsky EE, Domingo AT, Matuza NM, Taylor MB, Thode HC Jr, Singer AJ. Ibuprofen vs acetaminophen vs their combination in the relief of musculoskeletal pain in the ED: a randomized, controlled trial. Am J Emerg Med 2013; 31:1357-60.
    1. Woo WW, Man SY, Lam PK, Rainer TH. Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury. Ann Emerg Med 2005;46:352-61.
    1. Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder M. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev 2008;(1):CD000396.
    1. Rothberg S, Friedman BW. Complementary therapies in addition to medication for patients with nonchronic, nonradicular low back pain: a systematic review. Am J Emerg Med 2017;35:55-61.
    1. Friedman BW, Conway J, Campbell C, Bijur PE, Gallagher EJ. Pain one-week after an emergency department visit for acute low back pain Is associated with poor three-month outcomes. Acad Emerg Med 2018;25:1138-45.
    1. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet 2011;378:1560-71.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi